Onco-Summaries: Daily Oncology Updates at a Glance

25/03/2026

---

• Corcept's relacorilant + nab-paclitaxel received FDA approval for platinum-resistant Ovarian Cancer 

• TRIANA Biomedicines' TRI-611 received the FDA fast track designation for ALK+ NSCLC

• In a $6.7B deal, Merck & Co acquired Terns Pharmaceuticals to expand its hematology pipeline

---

Corcept's relacorilant + nab-paclitaxel received FDA approval for platinum-resistant Ovarian Cancer (Ref)

The US FDA granted approval to Corcept Therapeutics Incorporated's Lifyorli (relacorilant; selective glucocorticoid receptor antagonist) + nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

• The approval was based on the positive outcomes from Lifyorli's pivotal ROSELLA trial

• ROSELLA met its dual primary endpoints of PFS and OS

Return to Top

TRIANA Biomedicines' TRI-611 received the FDA fast track designation for ALK+ NSCLC (Ref)

The US FDA granted the fast track designation to TRIANA Biomedicines' TRI-611 (molecular glue degrader therapy) for the treatment of ALK+ NSCLC.

• Dr. Patrick Trojer, President and CEO, TRIANA: “This Fast Track designation underscores the potential of TRI-611 to address the significant unmet need for patients with ALK+ NSCLC who have been previously treated with two or more ALK tyrosine kinase inhibitors. TRI-611 was designed as an innovative therapeutic approach to target ALK fusion proteins. We look forward to working closely with the FDA to potentially bring TRI-611 forward to the lung cancer patient community.”

Return to Top

In a $6.7B deal, Merck & Co acquired Terns Pharmaceuticals to expand its hematology pipeline (Ref)

Merck & Co./MSD and Terns Pharmaceuticals entered into a definitive agreement under which Merck will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion.

• The transaction has been approved by both Merck’s and Terns’ Boards of Directors

• Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns

• Terns’ lead candidate, TERN-701 (oral allosteric BCR::ABL1 tyrosine kinase inhibitor), is currently being evaluated in the Phase 1/2 CARDINAL trial (NCT06163430) for patients with Ph+, chronic phase CML previously treated with at least one prior TKI and who experienced treatment failure, suboptimal response or treatment intolerance

  
  

Return to Top